Zacks Investment Research cut shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a hold rating to a sell rating in a research note released on Wednesday.
According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
BCRX has been the topic of a number of other research reports. ValuEngine upgraded BioCryst Pharmaceuticals from a buy rating to a strong-buy rating in a research note on Friday, October 12th. Royal Bank of Canada restated a buy rating and set a $9.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 7th. BidaskClub upgraded BioCryst Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, September 28th. Bank of America upgraded BioCryst Pharmaceuticals from an underperform rating to a neutral rating in a research note on Tuesday, July 17th. Finally, JPMorgan Chase & Co. initiated coverage on BioCryst Pharmaceuticals in a research note on Wednesday, August 8th. They set an overweight rating and a $9.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $9.89.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). The firm had revenue of $1.45 million for the quarter, compared to analysts’ expectations of $2.53 million. BioCryst Pharmaceuticals had a negative return on equity of 145.89% and a negative net margin of 428.00%. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.96 EPS for the current fiscal year.
In other BioCryst Pharmaceuticals news, insider Thomas R. Staab II sold 9,850 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the transaction, the insider now directly owns 140,633 shares in the company, valued at approximately $1,018,182.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Lynne Powell sold 5,280 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $8.15, for a total value of $43,032.00. Following the completion of the transaction, the vice president now owns 8,905 shares in the company, valued at $72,575.75. The disclosure for this sale can be found here. Insiders sold a total of 45,182 shares of company stock worth $352,176 over the last quarter. Company insiders own 4.50% of the company’s stock.
Several hedge funds have recently made changes to their positions in the business. American International Group Inc. grew its holdings in BioCryst Pharmaceuticals by 12.8% in the 3rd quarter. American International Group Inc. now owns 72,390 shares of the biotechnology company’s stock worth $552,000 after buying an additional 8,236 shares in the last quarter. BlackRock Inc. grew its holdings in BioCryst Pharmaceuticals by 13.1% in the 3rd quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock worth $66,914,000 after buying an additional 1,013,905 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in BioCryst Pharmaceuticals by 3.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 420,825 shares of the biotechnology company’s stock worth $3,211,000 after buying an additional 12,544 shares in the last quarter. Janus Henderson Group PLC grew its holdings in BioCryst Pharmaceuticals by 10.4% in the 3rd quarter. Janus Henderson Group PLC now owns 12,250,161 shares of the biotechnology company’s stock worth $93,469,000 after buying an additional 1,153,978 shares in the last quarter. Finally, Jennison Associates LLC grew its holdings in BioCryst Pharmaceuticals by 10.9% in the 3rd quarter. Jennison Associates LLC now owns 3,850,003 shares of the biotechnology company’s stock worth $29,376,000 after buying an additional 378,565 shares in the last quarter. Institutional investors own 79.82% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Read More: Book Value Per Share in Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.